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Since legalization of medical cannabis in Canada in 2001, there
has been growing interest in the use of medical cannabinoids
for treatment in children, fuelled by social media and a public
perception of safety and efficacy. Legalization of medical and
recreational cannabis appears to have, in some cases, altered the
public perception of potential benefit and harm. However, despite enthusiasm, there is scant evidence for efficacy of medical
cannabis for most health problems in children and there is concern as to potential for harm (1).
The disorders for which there is most evidence are neurological, specifically treatment-resistant epilepsy (2). There are clinical trials showing efficacy of high cannabinidiol (CBD) content
oil for this indication (3). Epidiolex is a high CBD content pharmacological preparation approved in the USA but not in Canada.
There is good evidence for efficacy of cannabis-derived products
as antiemetics; nabilone and dronabinol are synthetic cannabinoids approved for this indication. While there is promising
pilot work in areas such as autism, clear evidence for efficacy and
safety is lacking. There are clinical trials underway to evaluate the
use of medical cannabis for other conditions in children such as
spasticity and pain that hopefully will provide evidence to guide
the use (or non use) of medical cannabis for these conditions.
When deciding to authorize medical cannabis for a child,
a number of practical considerations must be borne in mind.
The decision to authorize use of medical cannabis for children
involves considerably more effort than the prescription of other
pharmaceuticals in that both patient/family and prescribers
must complete much more documentation to obtain access
to medical cannabis. An additional consideration is the degree
of comfort that the practitioner has with the disorder in question, as by and large the authorization of medical cannabis for
a child is the domain of sub-specialists, for example paediatric

epileptologists. In some circumstances authorizing and follow-up may be most appropriately done by a general paediatrician, in which case dialogue and frequent communication
between the paediatrician, family, and sub-specialist is essential.
If medical cannabis is a therapeutic consideration, there must be
a comprehensive conversation with patient and family as to potential benefits and potential risks attached to the use of medical cannabis. This may require more than one office visit and patience in
addressing both expectations and concerns is well advised and
should be well documented in the patient’s health records.
If the decision is made to proceed with authorizing medical
cannabis for a child, there are a series of decisions that need
to be made and communicated to the patient and family. The
first question is the therapeutic goal. What is the desired outcome and how and when will it be monitored? At what point
is success or lack of response determined? As well, the question of safety must be explored. Cannabinoids can produce a
number of adverse events, most commonly fatigue, drowsiness,
lethargy, abdominal pain, and diarrhoea. The patient and family
should be clear as to the potential for adverse effects, how to
deal with them and when to report them to the health care
team. The rate of significant adverse events varies but appears
to be dose dependent and ranges from 5 to 15% of patients (4).
Cannabinoids also are known to interact with other medications (5). As well, there are potential developmental issues in
children requiring fulsome consideration and discussion (1,6).
The next question relates to the type of medical cannabis.
Cannabis is a complex mixture of compounds, the two most
common being delta-9 tetrahydrocannabinol, which produces
euphoriant effects associated with marijuana, and CBD, which
is essential for antiepileptic effects. For seizures, high CBD
content preparations appear to be most effective. This raises

Received: September 24, 2019; Accepted: January 31, 2020
© The Author(s) 2020. Published by Oxford University Press on behalf of the Canadian Paediatric Society.
All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

S14

Downloaded from https://academic.oup.com/pch/article/25/Supplement_1/S14/5857596 by guest on 26 May 2021

Correspondence: Michael Rieder, Paediatric Clinical Pharmacology, Department of Paediatrics, Children’s Hospital of Western
Ontario, 800 Commissioner’s Road East, London, Ontario N6A 5W9, e-mail mrieder@uwo.ca

S15

Paediatrics & Child Health, 2020, Vol. 25, No. S1

formulations is not appropriate given the wide lot-to-lot variability in cannabinoid content.
The decision to authorize medical cannabinoids to children is difficult as is the authorization and monitoring process. Research is urgently needed to establish efficacy, safety
and to address the pragmatic issues facing clinicians and
families planning to use medical cannabinoids in children.
There are research teams, including the Canadian Paediatric
Surveillance Program, working to ensure that Canada is a leader in establishing the effective and safe use of medical cannabis in children.
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the question of dose. Trials have suggested a dose of CBD oil
between 5 and 20 mg/kg/day. A dose–efficacy relationship has
not been established but adverse effects seem to be more common at higher doses.
Many of these considerations apply to the authorizing of
any drug to children, but are coloured in the case of medical cannabis by social media and public perception. There
are also issues unique to medical cannabis. Once the cannabinoid of choice and dose have been selected, the next issue
is supply. Unlike other drugs, patients and their families may
have to deal directly with a licensed producer of medical cannabis. The selection of producer is critical, as it is important
that the cannabinoid used be in a child friendly formulation,
the concentration be consistent lot-to-lot and that there is an
assured supply. This often requires research on the part of the
treatment team and the family well beyond the norm for a
prescription.
Once a supplier has been identified, families face several
practical issues. The first is cost. Medical cannabinoids are not
inexpensive and do not have a Drug Identification Number
(DIN). Many insurance companies do not reimburse for products without a DIN, placing the burden of payment on the
family. An additional issue is palatability. Cannabionoid oils
are bitter and can be difficult to administer to young children.
Taste masking may be necessary. It cannot be over-emphasized that therapy should only be undertaken with cannabis
products designed for medical use, and that using edibles
intended for recreational use such as edible candy or ‘gummy’

